Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
05/20/19
Post-Hoc Analysis Highlights the Potential Role of YUPELRI in the COPD Treatment Paradigm Additional Analyses Demonstrate Commitment to Further Scientific Understanding of COPD DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , May 20, 2019 /PRNewswire/ -- Theravance Biopharma, Inc.
05/14/19
Presentation to Highlight Positive Data Demonstrating Clinical and Biomarker Activity Suggesting Localized Target Engagement and Minimal Systemic Exposure Following Four Weeks of Treatment in Patients with Moderately-to-Severely Active Ulcerative Colitis DUBLIN , May 14, 2019 /PRNewswire/ --
05/07/19
- Late-stage clinical studies of TD-1473 and ampreloxetine underway - Phase 1 results including biomarker data in asthmatics for lung-selective inhaled pan-JAK inhibitor TD-8236 expected in third quarter 2019 - Product launch of YUPELRI® (revefenacin) inhalation solution progressing in partnership
04/30/19
DUBLIN, Ireland , April 30, 2019 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended March 31, 2019 and provide a business update after market close on Tuesday, May 7, 2019
04/02/19
DUBLIN, Ireland , April 2, 2019 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in a fireside chat at the 18 th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 , at 9:20 a.m. ET .
03/25/19
Presentation to highlight data for novel, once-daily norepinephrine reuptake inhibitor in patients with neurogenic orthostatic hypotension 20-week data support previously-announced clinical observations after four weeks of treatment DUBLIN , March 25, 2019 /PRNewswire/ --  Theravance Biopharma,
03/12/19
Induction and maintenance portions of study to evaluate gut-selective pan-JAK inhibitor in patients with moderately to severely active ulcerative colitis DUBLIN , March 12, 2019 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced
02/26/19
YUPELRI™ (revefenacin) inhalation solution product launch progressing in partnership with Mylan Ampreloxetine and TD-1473 late-stage clinical programs advancing DUBLIN , Feb. 26, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (" Theravance Biopharma " or the "Company") (NASDAQ: TBPH) today
02/21/19
DUBLIN , Feb. 21, 2019 /PRNewswire/ --   Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 , at 9:00 a.m. ET .
02/19/19
In the news release, Theravance Biopharma to Report Fourth Quarter and Full Year 2018 Financial Results on February 26 , issued 19-Feb-2019 by Theravance Biopharma, Inc. over PR Newswire, we are advised by the company that date in the second paragraph, first sentence, should read " February 26,